<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01959633</url>
  </required_header>
  <id_info>
    <org_study_id>VEMUPLINT</org_study_id>
    <secondary_id>2013-003730-33</secondary_id>
    <nct_id>NCT01959633</nct_id>
  </id_info>
  <brief_title>Study of the Combination Vemurafenib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation</brief_title>
  <acronym>VEMUPLINT</acronym>
  <official_title>Phase I-II Study of the Combination Vemurafenib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Melanoma Onlus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Melanoma Onlus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this study is to evaluate the safety and the efficacy of
      Vemurafenib/PEG-interferon combination and the IFNAR1 upregulation lead by this treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I will include 9 patients with the common design 3+3+3. This phase will last until MTD
      is reached and patients who were part of the cohort selected due to MTD will be extended at
      phase II. In the phase II, 42 patients will be enrolled.

      Vemurafenib 960 mg b.i.d. + Peg-interferon 1/2/3 micrograms/Kg one time per week (until MTD
      reached) Interferon treatment should start after 15 days of Vemurafenib only. In the Phase I
      groups of 3 patients will be entered at each dose level (vemurafenib 960 mg b.i.d. +
      Peg-interferon 1/2/3 micrograms/Kg). If all 3 patients treated at a dose level have been
      observed for 2 courses of therapy without DLT, then the dose will be escalated.

      If at least 2/3 patients have DLT, then the previous dose level will be considered as the
      MTD. If 1/3 patients have DLT, then 3 more patients will be treated at this dose level. If
      none of these patients has DLT, then the dose will be escalated. If at least one of the 3
      additional patients has DLT, then the previous dose will be considered as MTD.

      This phase II is aimed:

      - to verify if the combination Vemurafenib plus PEG-interferon in advanced melanoma patients
      harboring the V600BRAF mutation is more active than the standard therapy (Vemurafenib) as
      reported in literature.

      Therefore, the lowest response probability of interest at 32 weeks is set to .40, and the
      combination treatment will be developed further only if the response at that time is at least
      .60.

      - to verify the upregulation of IFNAR1 expression in patients treated with the combination
      Vemurafenib plus PEG-interferon Therefore, the lowest expression probability of interest at 7
      days is set to .10, and the combination treatment will be developed further only if the
      expression is at least .90.

      Taking in account a 10% drop-out rate, a total of 48 patients will be enrolled to ensure a
      minimum of 42 evaluable patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>The NCI CTC-AE (Version 4) will be used to evaluate the clinical safety of the treatment in this study. Patients will be assessed for AEs at each clinical visit up to 24 weeks and as necessary throughout the study.
Hematology and biochemistry will be done as part of regular safety assessments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Objective tumor responses</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death for many cause, whichever came first, assessed up to week 32</time_frame>
    <description>Objective tumor response will be measured according to the modified RECIST 1.1 criteria. Response criteria are essentially based on a set of measurable lesions identified at baseline as target lesions, and followed until disease progression. Durable response rate (DRR) will be identified as the percentage of patients that is still in CR and PR at week 32. The results will be tabulated with Clopper-Pearson 95%CI for response rates</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>vemurafenib+ Peg-interferon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vemurafenib 960 mg b.i.d. + Peg-interferon 1/2/3 micrograms/Kg once weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vemurafenib</intervention_name>
    <description>Vemurafenib 960 mg b.i.d. for each course of treatment lasting 28 days</description>
    <arm_group_label>vemurafenib+ Peg-interferon</arm_group_label>
    <other_name>Brand name= Zelboraf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peg-interferon</intervention_name>
    <description>In the Phase I are included 3 cohorts. Cohort 1) Peg-interferon 1 µg/Kg one time per week s.c. Cohort 2) Peg-interferon 2 µg/Kg one time per week s.c. Cohort 3) Peg-interferon 3 µg/Kg one time per week s.c. Interferon treatment should start after 15 days of Vemurafenib only
In the Phase II is included the cohort selected by phase I due to MTD and expanded at RD.</description>
    <arm_group_label>vemurafenib+ Peg-interferon</arm_group_label>
    <other_name>Brand name= Sylatron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients over 18

          2. Untreated and pretreated (no more than 1 treatment) patients with metastatic melanoma
             at stage unreseactable IIIb-IV, histologically confirmed, that show V600 type BRAF
             mutations. Patients eligible for Phase I may have been pretreated with the
             investigational study treatments.

          3. Patient with measurable disease by RECIST v 1.1

          4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 - 1

          5. Patients who have successfully completed all the secondary side effects to previous
             systemic therapy

          6. Patients with an appropriate hematologic, hepatic and renal functionality, assessed in
             the 7 days preceding the start of therapy, as well as:

               -  Absolute neutrophil count (ANC)&gt; 1.5 X 109 / L

               -  Absolute platelet count &gt; 100 X 109 / L

               -  Hemoglobin &gt; 9 g/dl

               -  Serum creatinine &lt; 1.5 times the normal maximum values or Creatinine Clearance &gt;
                  50 mL/hr (Cockroft-Gault formula)

               -  Transaminase level (AST and ALT) &lt; 2.5 times the normal maximum values

               -  Serum bilirubin &lt; 1.5 times the normal maximum values

          7. Negative pregnancy test performed within 7 days before beginning therapy
             (premenopausal women)

          8. Patients of childbearing age (or with partners of childbearing age) must use effective
             contraception during therapy and for at least 6 months after the effective treatment

          9. Absence of any psychological, familiar or social condition that may affect compliance
             with study protocol and scheduled follow-up

         10. Dated and signed informed consent before any study procedure

        Exclusion Criteria:

          1. Presence of symptomatic brain metastases

          2. Previous malignant cancer during the 2 years preceding the signing of informed consent

          3. Investigational study treatment within 28 days or 5 half-lives, whichever is longer,
             preceding the first dose of study treatments in this study

          4. Pregnancy and/or breast feeding;

          5. Nausea and vomit refractory to therapy, malabsorption, external biliary shunt,
             previous bowel resection, which could impair an adequate absorption

          6. Any of these conditions occurring in the 6 months before the start of Vemurafenib
             therapy: heart attack, unstable angina and/or severe degree, congestive heart failure,
             cerebrovascular accident or transient ischemic attack, pulmonary embolism, arterial
             hypertension not adequately controlled

          7. History of atrial or ventricular arrhythmia, symptomatic&gt; grade 2 (NCI CTCAE)

          8. Hystory of retinopathy

          9. Correct QT interval &gt; 450msec to baseline history of congenital long QT syndrome

         10. Uncontrolled medical condition among which endocrine disorders (such as
             hypothyroidism, hyperthyroidism and diabetes mellitus)

         11. Other severe medical or psychiatric conditions or abnormalities of laboratory tests
             that may increase the risk associated with study participation or the assumption of
             Vemurafenib, or that may interfere with the interpretation of study results, which in
             the judgment of the Investigator can make the patient not eligible for the study

         12. Unwillingness to practice adequate contraception

         13. Prior systemic treatment with BRAFi or MEKi, or interferon alpha
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo A Ascierto, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fondazione Melanoma Onlus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paolo A Ascierto, MD</last_name>
    <phone>+390815903431</phone>
    <email>paolo.ascierto@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondazione G.Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paolo A Ascierto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Bukowski RM, Tendler C, Cutler D, Rose E, Laughlin MM, Statkevich P. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer. 2002 Jul 15;95(2):389-96. Review.</citation>
    <PMID>12124839</PMID>
  </reference>
  <reference>
    <citation>Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, Punt CJ, Delauney M, Sales F, Groenewegen G, Ruiter DJ, Jagiello I, Stoitchkov K, Keilholz U, Lienard D; EORTC Melanoma Group. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet. 2005 Oct 1;366(9492):1189-96.</citation>
    <PMID>16198768</PMID>
  </reference>
  <reference>
    <citation>Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Salès F, Gore M, Mackie R, Kusic Z, Dummer R, Hauschild A, Musat E, Spatz A, Keilholz U; EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008 Jul 12;372(9633):117-26. doi: 10.1016/S0140-6736(08)61033-8.</citation>
    <PMID>18620949</PMID>
  </reference>
  <reference>
    <citation>Eggermont AM, Suciu S, Testori A, Santinami M, Kruit WH, Marsden J, Punt CJ, Salès F, Dummer R, Robert C, Schadendorf D, Patel PM, de Schaetzen G, Spatz A, Keilholz U. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol. 2012 Nov 1;30(31):3810-8. doi: 10.1200/JCO.2011.41.3799. Epub 2012 Sep 24.</citation>
    <PMID>23008300</PMID>
  </reference>
  <reference>
    <citation>Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther. 2000 Nov;68(5):556-67.</citation>
    <PMID>11103758</PMID>
  </reference>
  <reference>
    <citation>Hwu WJ, Panageas KS, Menell JH, Lamb LA, Aird S, Krown SE, Williams LJ, Chapman PB, Livingston PO, Wolchok JD, Houghton AN. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. Cancer. 2006 Jun 1;106(11):2445-51.</citation>
    <PMID>16639739</PMID>
  </reference>
  <reference>
    <citation>Helfrich I, Edler L, Sucker A, Thomas M, Christian S, Schadendorf D, Augustin HG. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res. 2009 Feb 15;15(4):1384-92. doi: 10.1158/1078-0432.CCR-08-1615.</citation>
    <PMID>19228739</PMID>
  </reference>
  <reference>
    <citation>Sumimoto H, Hirata K, Yamagata S, Miyoshi H, Miyagishi M, Taira K, Kawakami Y. Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi. Int J Cancer. 2006 Jan 15;118(2):472-6.</citation>
    <PMID>16052531</PMID>
  </reference>
  <reference>
    <citation>Artale S, Sartore-Bianchi A, Veronese SM, Gambi V, Sarnataro CS, Gambacorta M, Lauricella C, Siena S. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol. 2008 Sep 1;26(25):4217-9. doi: 10.1200/JCO.2008.18.7286.</citation>
    <PMID>18757341</PMID>
  </reference>
  <reference>
    <citation>Leyton J, Smith G, Lees M, Perumal M, Nguyen QD, Aigbirhio FI, Golovko O, He Q, Workman P, Aboagye EO. Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. Mol Cancer Ther. 2008 Sep;7(9):3112-21. doi: 10.1158/1535-7163.MCT-08-0264.</citation>
    <PMID>18790789</PMID>
  </reference>
  <reference>
    <citation>Forbes SA, Tang G, Bindal N, Bamford S, Dawson E, Cole C, Kok CY, Jia M, Ewing R, Menzies A, Teague JW, Stratton MR, Futreal PA. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 2010 Jan;38(Database issue):D652-7. doi: 10.1093/nar/gkp995. Epub 2009 Nov 11.</citation>
    <PMID>19906727</PMID>
  </reference>
  <reference>
    <citation>Rubinstein JC, Sznol M, Pavlick AC, Ariyan S, Cheng E, Bacchiocchi A, Kluger HM, Narayan D, Halaban R. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med. 2010 Jul 14;8:67. doi: 10.1186/1479-5876-8-67.</citation>
    <PMID>20630094</PMID>
  </reference>
  <reference>
    <citation>Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D'Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010 Sep 30;467(7315):596-9. doi: 10.1038/nature09454.</citation>
    <PMID>20823850</PMID>
  </reference>
  <reference>
    <citation>Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, Kolis S, Zhao S, Lee R, Grippo JF, Schostack K, Simcox ME, Heimbrook D, Bollag G, Su F. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 2010 Jul 1;70(13):5518-27. doi: 10.1158/0008-5472.CAN-10-0646. Epub 2010 Jun 15. Erratum in: Cancer Res. 2010 Nov 15;70(22):9527.</citation>
    <PMID>20551065</PMID>
  </reference>
  <reference>
    <citation>Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010 Aug 26;363(9):809-19. doi: 10.1056/NEJMoa1002011.</citation>
    <PMID>20818844</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2013</study_first_submitted>
  <study_first_submitted_qc>October 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2013</study_first_posted>
  <last_update_submitted>January 18, 2017</last_update_submitted>
  <last_update_submitted_qc>January 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vemurafenib</mesh_term>
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

